Global Lymphoma Drugs Market 2017-2021

  • ID: 4307430
  • Report
  • Region: Global
  • 86 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
About Lymphoma Drugs
Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.

The analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Lymphoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Celgene
- F. Hoffmann-La Roche
- Johnson & Johnson
- Seattle Genetics

Other prominent vendors
- Amgen
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Novartis
- Pfizer
- Takeda Pharmaceuticals
- Teva Pharmaceutical Industries

Market drivers
- Increase in industry-academia collaborations
- For a full, detailed list, view the full report

Market challenges
- High cost of lymphoma treatment
- For a full, detailed list, view the full report

Market trends
- Increasing consolidation in the cancer treatment market
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key Market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are theKey vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
  • Lymphoma disease overview
PART 05: Market Introduction
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation by disease type
  • HL
  • NHL
PART 08: Geographical segmentation
  • Lymphoma drugs market in Americas
  • Lymphoma drugs market in EMEA
  • Lymphoma drugs market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Increasing consolidation in the cancer treatment market
  • Development of rituximab resistance leading to the development of new therapies
  • Studies performed to understand the genetics of lymphoma cells
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Celgene
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Seattle Genetics
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Types of lymphoma
Exhibit 02: Tests for lymphoma
Exhibit 03: Stages of lymphoma development
Exhibit 04: Treatment options for lymphoma
Exhibit 05: Global lymphoma drugs market snapshot
Exhibit 06: Global lymphoma drugs market 2016-2021($ millions)
Exhibit 07: Opportunity analysis in global lymphoma drugs market
Exhibit 08: Five forces analysis
Exhibit 09: Key pipeline drugs by vendors
Exhibit 10: Pipeline analysis
Exhibit 11: Segmentation of global lymphoma drugs market by disease type 2016
Exhibit 12: Market share of global lymphoma drugs market based on disease type 2016 and 2021
Exhibit 13: Subtypes of HL
Exhibit 14: Types of classic HL
Exhibit 15: Global HL drugs market 2016-2021 ($ millions)
Exhibit 16: Major drugs involved in HL drugs market
Exhibit 17: Types of NHL
Exhibit 18: Prevalence of various B-cell lymphoma in NHL
Exhibit 19: T-cell and natural killer cell lymphoma types
Exhibit 20: Global NHL drugs market 2016-2021 ($ millions)
Exhibit 21: Key highlights of NHL drugs market
Exhibit 22: Segmentation of global lymphoma drugs market based on geography 2016 and 2021
Exhibit 23: Global lymphoma drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 24: Market scenario in Americas
Exhibit 25: Lymphoma drugs market in Americas 2016-2021 ($ millions)
Exhibit 26: Incidence of NHL in Americas
Exhibit 27: Market scenario in EMEA
Exhibit 28: Lymphoma drugs market in EMEA 2016-2021 ($ millions)
Exhibit 29: Lymphoma cases in UK 2014
Exhibit 30: Incidence of NHL in EMEA
Exhibit 31: Market scenario in APAC
Exhibit 32: Lymphoma drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Incidence of NHL in APAC
Exhibit 34: Grants for research projects for NHL compared with total cancer researches 2016
Exhibit 35: Drugs and associated side effects
Exhibit 36: Competitive structure analysis of global lymphoma drugs market 2016
Exhibit 37: Strategic success factors of companies in global lymphoma drugs market
Exhibit 38: Celgene: Key highlights
Exhibit 39: Celgene: Strength assessment
Exhibit 40: Celgene: Strategy assessment
Exhibit 41: Celgene: Opportunity assessment
Exhibit 42: F. Hoffmann-La Roche: Key highlights
Exhibit 43: F. Hoffmann-La Roche: Strength assessment
Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Johnson & Johnson: Key highlights
Exhibit 47: Johnson & Johnson: Strength assessment
Exhibit 48: Johnson & Johnson: Strategy assessment
Exhibit 49: Johnson & Johnson: Opportunity assessment
Exhibit 50: Seattle Genetics: Key highlights
Exhibit 51: Seattle Genetics: Strength assessment
Exhibit 52: Seattle Genetics: Strategy assessment
Exhibit 53: Seattle Genetics: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
New Report Released: – Global Lymphoma Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global lymphoma drugs market: Celgene, F. Hoffmann-La Roche, Johnson & Johnson, and Seattle Genetics.

Other Prominent Vendors in the market are: Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increasing consolidation in the cancer treatment market. Past several years have witnessed significant consolidation in the cancer treatment industry. There can be seen a trend of movement of cancer treatment from clinics to hospitals. Studies have shown that there is a rise in a number of oncology clinics that got acquired by hospitals.”

According to the report, one of the major drivers for this market is increase in industry-academia collaborations. The key players in the market are increasingly extending their support to academic institutions to support the R&D of innovative drugs. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharmaceutical companies, besides providing funds to conduct trial studies. For instance, Merck's cancer segment collaborated with academic institutions such as BioMed X to support R&D activities in the development of monoclonal antibodies (mAbs) for cancer segment.

Further, the report states that one of the major factors hindering the growth of this market is high cost of lymphoma treatment. The high cost of treatment is a major problem for the lymphoma patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of lymphoma treatment. A large proportion of population either skip the treatment or leave it in the middle. Despite availing the costly treatment, reoccurrence of the disease quadruples the issues and negatively affects the patient adherence.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F.Hoffmann-La Roche
  • GlaxoSmithKline
  • Medlmmune
  • Pfizer
  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer HealthCare
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Immunomedics
  • Kedrion Biopharma
  • LFB Group
  • Merck
  • Novartis
  • Shire
  • Takeda Pharmaceuticals
  • UCB.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll